Back to Search Start Over

Adherence with tobramycin inhaled solution and health care utilization.

Adherence with tobramycin inhaled solution and health care utilization.

Authors :
Briesacher, Becky A.
Quittner, Alexandra L.
Saiman, Lisa
Sacco, Patricia
Fouayzi, Hassan
Quittell, Lynne M.
Source :
BMC Pulmonary Medicine; 2011, Vol. 11 Issue 1, p5-10, 6p
Publication Year :
2011

Abstract

Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization. Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories. Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768). Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712466
Volume :
11
Issue :
1
Database :
Complementary Index
Journal :
BMC Pulmonary Medicine
Publication Type :
Academic Journal
Accession number :
59182668
Full Text :
https://doi.org/10.1186/1471-2466-11-5